EGFR and head and neck squamous cell carcinoma: Currently, the only molecularly targeted drug approved for HNSCC is cetuximab, a monoclonal antibody that targets the EGFR, an antiapoptotic transmembrane protein which is amplified or overexpressed in the vast majority of HNSCC and is correlated with reduced survival[7].